Novartis Jul 19, 2022 Kisqali Shines as Novartis Posts Slight Decline in Q2 Revenues Jul 14, 2022 NICE Recommends Novartis' Piqray, Gilead's Trodelvy for Certain Breast Cancer Patients in England Jul 12, 2022 NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling Jun 28, 2022 European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients Jun 24, 2022 EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients Jun 23, 2022 MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients Premium Jun 23, 2022 Novartis Nets Tumor-Agnostic Approval for Tafinlar-Mekinist Combo Jun 22, 2022 European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC Jun 16, 2022 Ratio Therapeutics Launches to Develop More Target-Specific, Less Toxic Radiopharmaceuticals Premium Jun 9, 2022 Health Canada Approves Novartis' Tabrecta for NSCLC With METEx14 Skipping Alterations Jun 6, 2022 With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer Premium Jun 6, 2022 VISION Trial Sub-Studies Refine Pluvicto Benefit as Radiopharmaceutical Access Barriers Persist Premium May 31, 2022 Novartis' Kymriah Nabs FDA Approval in Refractory Follicular Lymphoma May 6, 2022 Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials May 5, 2022 Novartis Pauses US Pluvicto Production Due to Possible Quality Issues May 4, 2022 ESMO Breast Cancer Symposium Data Support First-Line CDK4/6 Inhibitor Combinations Premium May 4, 2022 Novartis Nabs European Approval for Kymriah in Follicular Lymphoma Apr 26, 2022 Novartis Q1 Revenues Grow 1 Percent Amid Organizational Restructuring, Shifting Growth Drivers Apr 22, 2022 EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation Apr 15, 2022 Novartis Enters KRAS G12C Space With Positive Phase I/II Data in Lung, Colorectal Cancer Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
